SLU-PP-332

Overview

SLU-PP-332 is a small-molecule (non-peptide) pan-agonist of estrogen-related receptors ERRα/β/γ developed at Saint Louis University. Studied preclinically as an exercise mimetic in rodents, it has no human clinical data and is NOT FDA-approved. Sold only as a grey-market research chemical.

Mechanism of Action

SLU-PP-332 activates all three ERR isoforms (α, β, γ) with highest potency at ERRα — orphan nuclear receptors that regulate oxidative metabolism gene programs. Activation drives PGC-1α co-activator pathways, mitochondrial biogenesis (TFAM, NRF1), fatty acid oxidation (CPT1B, ACADM), and slow-twitch type I muscle fiber specification. Note: despite the ERR name, these receptors do not bind estrogen.

Research Summary

Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.

Dosing Information

Reported Side Effects

• No human safety data — preclinical only
• Unknown long-term toxicity profile
• Potential off-target nuclear receptor interactions
• Unknown cardiovascular, hepatic, and reproductive risk in humans

Research References

• Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (ACS Chem Biol) (2023)
• A Synthetic ERR Agonist Alleviates Metabolic Syndrome (J Pharmacol Exp Ther) (2024)